Zombie Vortex Instability. II. Thresholds to Trigger Instability and the Properties of Zombie Turbulence in the Dead Zones of Protoplanetary Disks

In Zombie Vortex Instability (ZVI), perturbations excite critical layers in stratified, rotating shear flow (as in protoplanetary disks), causing them to generate vortex layers, which roll-up into anticyclonic zombie vortices and cyclonic vortex sheets. The process is self-sustaining as zombie vortices perturb new critical layers, spawning a next generation of zombie vortices. Here, we focus on two issues: the minimum threshold of perturbations that trigger self-sustaining vortex generation, and the properties of the late-time zombie turbulence on large and small scales. The critical parameter that determines whether ZVI is triggered is the magnitude of the vorticity on the small scales (and not velocity), the minimum Rossby number needed for instability is $Ro_{crit}\sim0.2$ for $\beta\equiv N/\Omega = 2$, where $N$ is the Brunt-V\"ais\"al\"a frequency. While the threshold is set by vorticity, it is useful to infer a criterion on the Mach number, for Kolmogorov noise, the critical Mach number scales with Reynolds number: $Ma_{crit}\sim Ro_{crit}Re^{-1/2}$. In protoplanetary disks, this is $Ma_{crit}\sim10^{-6}$. On large scales, zombie turbulence is characterized by anticyclones and cyclonic sheets with typical Rossby number $\sim$0.3. The spacing of the cyclonic sheets and anticyclones appears to have a "memory" of the spacing of the critical layers. On the small scales, zombie turbulence has no memory of the initial conditions and has a Kolmogorov-like energy spectrum. While our earlier work was in the limit of uniform stratification, we have demonstrated that ZVI works for non-uniform Brunt-V\"ais\"al\"a frequency profiles that may be found in protoplanetary disks.Comment: Submitted to Ap

Three-Dimensional Simulations of Kelvin-Helmholtz Instability in Settled Dust Layers in Protoplanetary Disks

As dust settles in a protoplanetary disk, a vertical shear develops because the dust-rich gas in the midplane orbits at a rate closer to true Keplerian than the slower-moving dust-depleted gas above and below. A classical analysis (neglecting the Coriolis force and differential rotation) predicts that Kelvin-Helmholtz instability occurs when the Richardson number of the stratified shear flow is below roughly one-quarter. However, earlier numerical studies showed that the Coriolis force makes layers more unstable, whereas horizontal shear may stabilize the layers. Simulations with a 3D spectral code were used to investigate these opposing influences on the instability in order to resolve whether such layers can ever reach the dense enough conditions for the onset of gravitational instability. I confirm that the Coriolis force, in the absence of radial shear, does indeed make dust layers more unstable, however the instability sets in at high spatial wavenumber for thicker layers. When radial shear is introduced, the onset of instability depends on the amplitude of perturbations: small amplitude perturbations are sheared to high wavenumber where further growth is damped; whereas larger amplitude perturbations grow to magnitudes that disrupt the dust layer. However, this critical amplitude decreases sharply for thinner, more unstable layers. In 3D simulations of unstable layers, turbulence mixes the dust and gas, creating thicker, more stable layers. I find that layers with minimum Richardson numbers in the approximate range 0.2 -- 0.4 are stable in simulations with horizontal shear.Comment: 33 pages, 11 figures (5 color, low-resolution versions), Submitted to The Astrophysical Journal, see http://www.physics.sfsu.edu/~barranco for higher resolution color figures and associated avi animation file

Phases of planar 5-dimensional supersymmetric Chern-Simons theory

In this paper we investigate the large-$N$ behavior of 5-dimensional $\mathcal{N}=1$ super Yang-Mills with a level $k$ Chern-Simons term and an adjoint hypermultiplet. As in three-dimensional Chern-Simons theories, one must choose an integration contour to completely define the theory. Using localization, we reduce the path integral to a matrix model with a cubic action and compute its free energy in various scenarios. In the limit of infinite Yang-Mills coupling and for particular choices of the contours, we find that the free-energy scales as $N^{5/2}$ for $U(N)$ gauge groups with large values of the Chern-Simons 't\,Hooft coupling, $\tilde\lambda\equiv N/k$. If we also set the hypermultiplet mass to zero, then this limit is a superconformal fixed point and the $N^{5/2}$ behavior parallels other fixed points which have known supergravity duals. We also demonstrate that $SU(N)$ gauge groups cannot have this $N^{5/2}$ scaling for their free-energy. At finite Yang-Mills coupling we establish the existence of a third order phase transition where the theory crosses over from the Yang-Mills phase to the Chern-Simons phase. The phase transition exists for any value of $\tilde\lambda$, although the details differ between small and large values of $\tilde\lambda$. For pure Chern-Simons theories we present evidence for a chain of phase transitions as $\tilde\lambda$ is increased. We also find the expectation values for supersymmetric circular Wilson loops in these various scenarios and show that the Chern-Simons term leads to different physical properties for fundamental and anti-fundamental Wilson loops. Different choices of the integration contours also lead to different properties for the loops.Comment: 40 pages, 17 figures, Minor corrections, Published versio

In-Orbit Performance of the GRACE Follow-on Laser Ranging Interferometer

The Laser Ranging Interferometer (LRI) instrument on the Gravity Recovery and Climate Experiment (GRACE) Follow-On mission has provided the first laser interferometric range measurements between remote spacecraft, separated by approximately 220 km. Autonomous controls that lock the laser frequency to a cavity reference and establish the 5 degrees of freedom two-way laser link between remote spacecraft succeeded on the first attempt. Active beam pointing based on differential wave front sensing compensates spacecraft attitude fluctuations. The LRI has operated continuously without breaks in phase tracking for more than 50 days, and has shown biased range measurements similar to the primary ranging instrument based on microwaves, but with much less noise at a level of 1 nm/Hz at Fourier frequencies above 100 mHz. © 2019 authors. Published by the American Physical Society

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Measurement of the inclusive isolated-photon cross section in pp collisions at √s = 13 TeV using 36 fb−1 of ATLAS data

The differential cross section for isolated-photon production in pp collisions is measured at a centre-of-mass energy of 13 TeV with the ATLAS detector at the LHC using an integrated luminosity of 36.1 fb. The differential cross section is presented as a function of the photon transverse energy in different regions of photon pseudorapidity. The differential cross section as a function of the absolute value of the photon pseudorapidity is also presented in different regions of photon transverse energy. Next-to-leading-order QCD calculations from Jetphox and Sherpa as well as next-to-next-to-leading-order QCD calculations from Nnlojet are compared with the measurement, using several parameterisations of the proton parton distribution functions. The predictions provide a good description of the data within the experimental and theoretical uncertainties. [Figure not available: see fulltext.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years